BioCryst Pharmaceuticals (BCRX) stock is in focus after third quarter results showed revenue of US$180.29 million and net income of US$37.92 million, along with higher full year 2026 revenue guidance. Against that earnings backdrop, BioCryst Pharmaceuticals shares have been under pressure in recent months, with the 30 day share price return down 8.45% and the 90 day move down 18.02%. However, the year to date share price return is positive at 2.53% and the 3 year total shareholder return is...
Motley Fool Press Release.
(AP) — BioCryst Pharmaceuticals Inc. (BCRX) on Wednesday reported third-quarter earnings of $37.
— Total net revenue of $180.3 million and ORLADEYO® net revenue of $174.8 million — — Operating profit of $53.3 million and Non-GAAP operating profit of $86.5 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $715 million to $730 million — — Improved Non-GAAP operating expense guidance to $415 to $425 million — — Received FDA approval for ORLADEYO 150 mg oral pellets for patients aged 12 and older — RESEARCH TRIANGLE P
—New data highlight BioCryst's commitment to advancing a portfolio of therapies for people living with HAE— RESEARCH TRIANGLE PARK, N.C., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that four abstracts from its hereditary angioedema (HAE) portfolio have been accepted for presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting taking place in Phoenix, Arizona, November 12-16. BioCryst will pres
Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.
BioCryst Pharmaceuticals (NASDAQ:BCRX) is shifting its strategy toward external innovation as it seeks to expand beyond its ORLADEYO hereditary angioedema, or HAE, franchise, newly appointed Chief Executive Officer Charlie Gayer said at a Morgan Stanley event. Gayer, who became CEO on Jan. 1, said
On August 28, 2026, CNBC reported that BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), now consistently profitable on the strength of its hereditary angioedema drug “Orladeyo,” is looking to acquire more rare disease treatments, according to CEO Charlie Gayer. Gayer, who took the role in January, said the company expects to keep growing profits every year and does […]
BioCryst Pharmaceuticals (BCRX) has drawn fresh attention after recent trading left the share price at US$8.12, with the stock down over the past week and month but modestly higher year to date. Recent trading tells a mixed story for BioCryst Pharmaceuticals, with the share price falling 18.47% over the past week and 16.63% over the past month, yet still showing an 8.27% year to date share price return and a 5.45% one year total shareholder return. This suggests that short term momentum is...
NEW HYDE PARK, N.Y., Sept. 08, 2026 (GLOBE NEWSWIRE) -- CareMed, an independent specialty pharmacy, has been selected as a pharmacy partner by BioCryst Pharmaceuticals for Orladeyo® (berotralstat), a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older.1 “The addition of Orladeyo reinforces our long-term commitment to supporting rare and complex disease, highlights the strength of our specialty
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET. The link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at www.biocryst.com. About BioCryst Pharmaceuticals BioCryst is a global biote
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
CEO Gayer told CNBC in an interview that the company is now profitable and plans to use that cash to invest in other rare-disease medicines.
The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Rare disease drug development is getting a boost from new funding models and a growing group of smaller biotech buyers.
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to <12 years in Japan — RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing approval for once-daily ORLADEYO® (berotralstat) for prophylactic therapy in pediatric patients with hereditary angioedema (HAE) aged 2 to <12 years. “The approval of ORL
This is the newest page. Registered accounts read further back.